Report Description Table of Contents How Are Cardiovascular Disease Burden and Preventive Screening Driving Growth in the Global Cholesterol Testing Market? – (Updated On: 12th-Oct-2026) The Global Cholesterol Testing Market was valued at USD 18.88 billion in 2025 and is projected to reach USD 30.20 billion by 2032, expanding at a CAGR of 6.94% during 2026–2032, according to Strategic Market Research. Market growth is supported by routine cardiovascular risk screening, increasing identification of abnormal cholesterol levels, and recurring lipid monitoring among patients receiving cholesterol-lowering treatment. Demand spans laboratory lipid panels, diagnostic reagents, automated analyzers, and point-of-care testing systems. High cholesterol screening participation in the United States demonstrates substantial diagnostic demand. According to a CDC study published in March 2026 involving 383,892 U.S. adults, approximately 85.6% reported cholesterol screening within the previous five years, compared with 77.4% among adults aged 18–44. Among previously screened individuals, 33.2% reported having been informed of high cholesterol. These findings indicate a substantial population requiring cardiovascular risk assessment and potential follow-up testing. Abnormal cholesterol levels are creating continued demand for LDL and HDL testing. CDC data from August 2021–August 2023 found that 11.3% of U.S. adults aged 20 and older had high total cholesterol, while 13.8% had low HDL cholesterol. Low HDL prevalence was particularly pronounced among men at 21.5%, compared with 6.6% among women. These findings support the importance of lipid testing in preventive healthcare and ongoing cardiovascular risk management. Automated laboratory testing and expanded diagnostic access are creating opportunities for equipment and reagent suppliers. Roche Diagnostics, Abbott Laboratories, and Siemens Healthineers supply clinical chemistry platforms supporting routine cholesterol measurement. Increasing demand for efficient laboratory workflows, repeat lipid testing, and accessible preventive screening is supporting opportunities for diagnostic manufacturers, clinical laboratories, and point-of-care testing providers. Segment Analysis — Which Cholesterol Testing Segments Lead Revenue and Which Offer the Fastest Growth? By Product Type: Testing Kits Lead Revenue While Analyzers Benefit from Automation Leading Subsegment — Cholesterol Testing Kits Cholesterol testing kits accounted for an estimated 41% of the global Cholesterol Testing Market, valued at USD 7.741 billion in 2025, and are projected to grow at a CAGR of 6.46% during 2026–2032. Their strong market position reflects increasing adoption of convenient, home-based cholesterol screening and regular blood lipid monitoring. Growing awareness of cardiovascular health, preventive screening initiatives, and wider availability of portable testing solutions support market expansion. Cholesterol testing kits also complement professional diagnostic services by enabling individuals to monitor lipid levels between clinical consultations. Fastest-Growing Subsegment — Cholesterol Testing Analyzers Cholesterol testing analyzers measure lipid concentrations in blood or serum samples, supporting cardiovascular risk assessment and the early identification of conditions associated with heart disease and stroke. In 2025, cholesterol testing analyzers accounted for approximately 24% of the global Cholesterol Testing Market, valued at USD 4.531 billion, and are projected to grow at a CAGR of 7.76% during 2026–2032. Increasing lipid screening across hospitals, diagnostic laboratories, and preventive healthcare programs is supporting analyzer adoption for routine cholesterol monitoring and cardiovascular disease management. By Test Type: Complete Lipid Panels Dominate While LDL Testing Expands Leading Subsegment — Lipid Panel / Complete Lipid Profile Complete lipid panels accounted for approximately 48% of the global Cholesterol Testing Market, valued at USD 9.062 billion in 2025, and are projected to expand at a CAGR of 7.41% during 2026–2032. Complete lipid panels measure total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides in the blood to assess cardiovascular disease risks, including heart attacks and strokes. Their widespread use in routine health screenings, cardiovascular risk assessment, and ongoing cholesterol management supports their leading position in cholesterol testing across hospitals and diagnostic laboratories. Fastest-Growing Subsegment — LDL Cholesterol Tests LDL cholesterol testing measures low-density lipoprotein, commonly known as bad cholesterol, to assess the risk of arterial plaque buildup, cardiovascular disease, and stroke. As a key component of routine lipid panels, LDL testing supports cardiovascular risk assessment, preventive screening, and ongoing cholesterol management. Within the global Cholesterol Testing Market, LDL cholesterol tests accounted for an estimated 15% market share, valued at USD 2.832 billion in 2025, and are projected to grow at a CAGR of 7.61% during 2026–2032, supported by widespread cardiovascular screening and preventive healthcare initiatives. By Technology: Enzymatic Assays Maintain Leadership While Biosensors Accelerate Growth Leading Subsegment — Enzymatic Assays Enzymatic assays accounted for an estimated 59% share of the global Cholesterol Testing Market, generating USD 11.139 billion in 2025, and are projected to grow at a CAGR of 6.32% during 2026–2032. Enzymatic methods remain the gold standard for measuring cholesterol levels in clinical laboratories and point-of-care settings due to their high accuracy, sensitivity, rapid processing, and compatibility with automated testing systems. Their widespread use in routine lipid profiling, cardiovascular risk assessment, and preventive health screening supports their leading position across cholesterol testing applications worldwide. Fastest-Growing Subsegment — Electrochemical Biosensors Electrochemical biosensors accounted for approximately 20% of the global Cholesterol Testing Market in 2025, representing a market value of USD 3.776 billion, and are projected to register the fastest CAGR of 10.02% during 2026–2032. Electrochemical biosensors measure cholesterol by converting biochemical recognition events into electrical signals, enabling rapid and accurate cholesterol assessment. Their growing use in point-of-care testing, portable diagnostic devices, and routine cardiovascular risk monitoring is supporting wider adoption across hospitals, diagnostic laboratories, and home-based cholesterol testing applications. By Application: Cardiovascular Screening Drives Revenue While Preventive Testing Expands Leading Subsegment — Cardiovascular Disease Screening & Management Cholesterol testing plays a critical role in cardiovascular disease (CVD) screening and management by identifying abnormal lipid levels before they contribute to arterial blockages, heart attacks, or strokes. Cardiovascular disease screening and management accounted for an estimated 45% of the global Cholesterol Testing Market, valued at USD 8.496 billion in 2025, and is projected to expand at a CAGR of 6.72% during 2026–2032. Increasing emphasis on early cardiovascular risk assessment, routine lipid profiling, and preventive care supports continued testing across hospitals, diagnostic laboratories, and primary care settings. Fastest-Growing Subsegment — Preventive Health Screening Preventive health screening accounted for approximately 15% of the global Cholesterol Testing Market, valued at USD 2.832 billion in 2025, and is projected to grow at a CAGR of 8.72% during 2026–2032. Preventive cholesterol testing through lipid profile examinations helps identify elevated cholesterol levels and cardiovascular risks before symptoms develop. Growing emphasis on early detection of dyslipidemia, routine cardiovascular risk assessments, and periodic cholesterol monitoring among adults is supporting wider adoption of preventive screening across hospitals, diagnostic laboratories, and primary healthcare facilities. By End User: Hospitals Lead Diagnostic Revenue While Home Healthcare Gains Momentum Leading Subsegment — Hospitals & Clinics Hospitals and clinics accounted for an estimated 40% of the global cholesterol testing market, valued at USD 7.552 billion in 2025, and are projected to grow at a CAGR of 6.30% during 2026–2032. Their leading position reflects the widespread use of comprehensive lipid panel blood tests for cardiovascular risk assessment, cholesterol monitoring, and long-term heart health management. Increasing preventive health screenings, routine cholesterol evaluations, and follow-up testing among patients with cardiovascular conditions continue to support cholesterol testing activity across hospital laboratories and outpatient clinics. Fastest-Growing Subsegment — Home Healthcare At-home cholesterol testing provides individuals with a convenient and private option for monitoring blood lipid levels, particularly among people managing cardiovascular risk factors. Home healthcare accounted for approximately 14% of the global cholesterol testing market in 2025, representing USD 2.643 billion in market value. The category is projected to register the fastest CAGR of 9.90% during 2026–2032, supported by growing adoption of home-based lipid screening and portable testing devices. However, professional laboratory testing and clinical supervision remain essential for accurate diagnosis and treatment decisions. By Age Group: Geriatric Testing Leads While Adult Screening Offers Faster Expansion Leading Subsegment — Geriatric Population The geriatric population accounted for an estimated 52% of the global Cholesterol Testing Market, valued at USD 9.818 billion in 2025, and is projected to grow at a CAGR of 6.46% during 2026–2032. Hypercholesterolemia affects approximately 30.6% to 91.7% of adults aged 65 and older globally, highlighting the importance of regular cholesterol screening and cardiovascular risk assessment. Age-related changes in lipid levels, higher cardiovascular disease prevalence, and ongoing treatment monitoring support cholesterol testing across elderly populations. Fastest-Growing Subsegment — Adult Population The adult population accounted for an estimated 40% share of the global cholesterol testing market, valued at USD 7.552 billion in 2025, and is projected to grow at a CAGR of 7.76% during 2026–2032. Adults represent a major population group for cholesterol screening, driven by the need for early detection of elevated cholesterol levels, lifetime cardiovascular risk assessment, and preventive management of atherosclerosis. Increasing awareness of cardiovascular health, routine lipid profile screening, and regular monitoring among individuals with hypertension, diabetes, and obesity further support cholesterol testing adoption. By Geography: North America Maintains Revenue Leadership While Asia-Pacific Accelerates Leading Region — North America North America accounted for an estimated 37% share of the global Cholesterol Testing Market, valued at USD 6.986 billion in 2025, and is projected to grow at a CAGR of 6.14% during 2026–2032. Cholesterol testing is firmly established in routine healthcare across the region, supported by preventive screening programs, cardiovascular risk assessments, and established clinical guidelines. The United States leads regional testing activity, with regular lipid profile screening, increasing attention to high cholesterol, and broader access to diagnostic laboratories supporting continued market expansion. Fastest-Growing Region — Asia-Pacific Asia-Pacific is undergoing a significant shift in cholesterol testing, driven by the rising prevalence of cardiovascular diseases, diabetes, and obesity, alongside expanding preventive screening programs and updated clinical guidelines. The region accounted for approximately 26% of the global market, valued at USD 4.909 billion in 2025, and is projected to register the fastest regional CAGR of 8.94% during 2026–2032. Increasing lipid profile testing, wider access to diagnostic laboratories, and growing cardiovascular risk assessment initiatives across China, India, and Japan support regional expansion. Competitive Landscape — How Are Leading Diagnostic Companies Advancing Cholesterol Testing Technologies? Roche Diagnostics — Leading Competitor in Automated Cholesterol Testing Roche Diagnostics maintains a strong competitive position through its cobas clinical chemistry platforms and lipid testing assays. The company's portfolio supports total cholesterol, HDL cholesterol, triglyceride measurement, and LDL cholesterol assessment across automated laboratory and selected near-patient settings. Its cobas b 101 lipid panel uses photometric measurement technology, supporting cholesterol assessment outside centralized laboratories. In 2025, Roche's Diagnostics Division generated CHF 13.847 billion in revenue, while its Core Lab business contributed CHF 7.614 billion, representing approximately 55% of diagnostics sales. Roche also reported introducing 53 new diagnostic tests, two instrument platforms, and six digital solutions during 2025. These figures demonstrate the scale of its broader diagnostics operations rather than cholesterol-testing-specific sales. Roche's competitive advantage lies in its established analyzer base, recurring reagent business, and ability to serve both high-volume laboratories and near-patient testing environments. Abbott Laboratories — Leading Competitor in High-Volume Clinical Chemistry Testing Abbott Laboratories holds a strong position in cholesterol testing through its Alinity c and ARCHITECT clinical chemistry platforms. These systems support lipid profile testing for cardiovascular screening, dyslipidemia diagnosis, and treatment monitoring. Abbott's Alinity c platform uses photometric and potentiometric measurement technologies and supports a maximum throughput of 1,350 tests per hour, depending on assay configuration. Its automated testing capabilities support laboratories handling substantial volumes of routine cholesterol and metabolic testing. In 2025, Abbott reported USD 8.937 billion in global Diagnostics revenue, including USD 5.360 billion from Core Laboratory Diagnostics. Core Laboratory sales increased 2.4% on a reported basis compared with 2024. Abbott's established laboratory platforms and recurring reagent sales provide a commercial foundation for cholesterol testing. Its competitive strength is particularly relevant to hospital laboratories and diagnostic networks seeking to consolidate multiple routine chemistry tests onto automated platforms. Other Key Companies and Their Roles in Cholesterol Testing: Siemens Healthineers: Supplies Atellica clinical chemistry platforms and lipid assays that support automated cholesterol screening and monitoring in hospital and diagnostic laboratories. Beckman Coulter Diagnostics: Offers AU clinical chemistry analyzers and lipid testing reagents for high-volume cholesterol testing in centralized laboratories. PTS Diagnostics: Provides CardioChek Plus analyzers capable of delivering lipid panel results in as little as 90 seconds using a 40 µL blood sample, supporting decentralized cardiovascular screening. ACON Laboratories: Offers Mission cholesterol monitoring systems using reflectance photometry and biosensor technology; its Mission Ultra system can provide total cholesterol results in as little as 15 seconds, supporting portable testing applications. Analyst Commentary: How Will Repeat Lipid Testing and Wider Screening Access Shape the Cholesterol Testing Market? The cholesterol testing market's next phase of growth will depend increasingly on how frequently lipid abnormalities are identified and monitored, rather than on initial screening alone. Rising cardiovascular risk among younger adults, growing demand for LDL cholesterol monitoring, and wider use of preventive health screening are creating opportunities for repeat testing. Point-of-care lipid testing and portable monitoring technologies could improve screening accessibility, particularly in underserved populations. However, affordability, diagnostic accuracy, and consistent follow-up testing will remain important factors determining how effectively unmet screening needs translate into sustained market demand. Cholesterol Testing Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 18.88 Billion Revenue Forecast in 2032 USD 30.20 Billion Overall Growth Rate CAGR of 6.94% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million/Billion, CAGR (2026 – 2032) Segmentation By Product Type, By Test Type, By Technology, By Application, By End User, By Age Group, By Geography By Product Type Cholesterol Testing Kits, Cholesterol Testing Strips, Cholesterol Testing Analyzers, Other Testing Consumables By Test Type Lipid Panel / Complete Lipid Profile, Total Cholesterol Tests, HDL Cholesterol Tests, LDL Cholesterol Tests, Triglyceride Tests By Technology Enzymatic Assays, Colorimetric Testing, Electrochemical Biosensors, Other Technologies By Application Cardiovascular Disease Screening & Management, Hyperlipidemia Diagnosis & Monitoring, Preventive Health Screening, Diabetes & Metabolic Disease Management, Other Applications By End User Hospitals & Clinics, Diagnostic Laboratories, Home Healthcare, Ambulatory Care Centers, Other End Users By Age Group Pediatric Population, Adult Population, Geriatric Population By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers High cardiovascular disease burden, increasing cholesterol screening participation, rising prevalence of abnormal cholesterol levels, growing demand for routine lipid panels and LDL monitoring, expansion of preventive health screening, increasing adoption of automated laboratory analyzers, growth of point-of-care cholesterol testing, rising home-based lipid monitoring, and expanding access to decentralized diagnostic technologies Customization Option Available upon request Frequently Asked Question About This Report Q1. Why is preventive screening becoming more important in the market? A1. Preventive screening helps identify abnormal cholesterol levels before cardiovascular symptoms develop. High screening participation and growing awareness of long-term heart risk are increasing demand for repeat lipid testing. Q2. What are the latest technology trends shaping the industry? A2. The industry is moving toward automated analyzers, electrochemical biosensors, portable lipid testing systems, and decentralized diagnostics. These technologies support faster testing across laboratories, clinics, and home healthcare settings. Q3. Why is LDL testing gaining stronger importance in the market? A3. LDL testing plays a central role in cardiovascular risk assessment and monitoring cholesterol-lowering treatment. Increasing emphasis on controlling atherosclerotic risk is supporting more frequent LDL measurement. Q4. How is home healthcare influencing the industry? A4. Home healthcare is expanding through portable cholesterol devices and convenient self-monitoring options. This enables individuals to track lipid levels between clinical visits while supporting wider access to preventive screening. Q5. Which application is creating the fastest growth opportunity in the market? A5. Preventive health screening is projected to record the fastest application CAGR of 8.72% during 2026–2032. Routine health checkups and earlier identification of dyslipidemia are expanding testing among adults before cardiovascular disease develops. Q6. Which region is expected to record the fastest growth in the industry? A6. Asia-Pacific is projected to record the fastest regional CAGR of 8.94% during 2026–2032. Growth is supported by expanding diagnostic access, rising cardiovascular risk, and wider preventive screening across China, India, Japan, and South Korea. Sources: CDC – 383,892-Adult Study: 85.6% Had Cholesterol Screening Within Five Years; 33.2% Reported High Cholesterol CDC – Cholesterol Screening and High Cholesterol Study, 2026 CDC/NCHS – 11.3% of U.S. Adults Had High Total Cholesterol; 13.8% Had Low HDL, Including 21.5% of Men CDC – Total and HDL Cholesterol in U.S. Adults CDC – Lipid Profile Testing Measures LDL, HDL and Triglycerides for Cardiovascular Risk Assessment CDC – Testing for Cholesterol Roche – 2025 Diagnostics Sales of CHF 13.847 Billion; Core Lab Sales of CHF 7.614 Billion Roche – 2025 Full-Year Results Roche Diagnostics – cobas Lipid Panel Gen. 2 Measures Total Cholesterol, HDL, Triglycerides and Calculates LDL Roche – cobas Lipid Panel Gen. 2 Abbott – USD 8.937 Billion Diagnostics Revenue and USD 5.360 Billion Core Laboratory Revenue in 2025; Alinity and ARCHITECT Support Clinical Chemistry Testing SEC – Abbott 2025 Annual Report Siemens Healthineers – Atellica Clinical Chemistry Platforms Support Total Cholesterol, HDL, LDL and Triglyceride Testing Siemens Healthineers – Atellica CI Analyzer PTS Diagnostics – CardioChek Plus Provides a Full Lipid Panel in as Little as 90 Seconds From a 40 µL Fingerstick Sample PTS Diagnostics – CardioChek Plus Table of Contents - Global Cholesterol Testing Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Product Type, Test Type, Technology, Application, End User, Age Group, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Product Type, Test Type, Technology, Application, End User, Age Group, and Region Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Product Type, Test Type, Technology, Application, End User, and Age Group Investment Opportunities in the Cholesterol Testing Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Cholesterol Testing Kits, Testing Strips, Automated Analyzers, Complete Lipid Profiles, LDL Cholesterol Testing, Electrochemical Biosensors, Preventive Health Screening, and Home Healthcare Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of Cholesterol Testing in Cardiovascular Risk Assessment, Hyperlipidemia Diagnosis, Preventive Healthcare, and Long-Term Lipid Monitoring Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Diagnostic Regulations, Laboratory Standards, and Quality Compliance Factors Role of Cardiovascular Disease Screening, Complete Lipid Profiles, LDL Cholesterol Testing, and Preventive Health Programs in Market Expansion Diagnostic Accuracy, Automated Laboratory Workflows, Point-of-Care Accessibility, and Home-Based Lipid Monitoring Trends Global Cholesterol Testing Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type: Cholesterol Testing Kits Cholesterol Testing Strips Cholesterol Testing Analyzers Other Testing Consumables Market Analysis by Test Type: Lipid Panel / Complete Lipid Profile Total Cholesterol Tests HDL Cholesterol Tests LDL Cholesterol Tests Triglyceride Tests Market Analysis by Technology: Enzymatic Assays Colorimetric Testing Electrochemical Biosensors Other Technologies Market Analysis by Application: Cardiovascular Disease Screening & Management Hyperlipidemia Diagnosis & Monitoring Preventive Health Screening Diabetes & Metabolic Disease Management Other Applications Market Analysis by End User: Hospitals & Clinics Diagnostic Laboratories Home Healthcare Ambulatory Care Centers Other End Users Market Analysis by Age Group: Pediatric Population Adult Population Geriatric Population Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Cholesterol Testing Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Test Type, Technology, Application, End User, and Age Group Country-Level Breakdown: United States Canada Mexico Europe Cholesterol Testing Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Test Type, Technology, Application, End User, and Age Group Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific Cholesterol Testing Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Test Type, Technology, Application, End User, and Age Group Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America Cholesterol Testing Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Test Type, Technology, Application, End User, and Age Group Country-Level Breakdown: Brazil Argentina Rest of Latin America Middle East & Africa Cholesterol Testing Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Test Type, Technology, Application, End User, and Age Group Country-Level Breakdown: GCC Countries South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Roche Diagnostics Abbott Laboratories Siemens Healthineers Beckman Coulter Diagnostics PTS Diagnostics ACON Laboratories Sekisui Diagnostics Randox Laboratories Thermo Fisher Scientific Mindray Medical International Competitive Landscape and Strategic Insights Benchmarking Based on Product Portfolio, Test Menu, Analyzer Compatibility, Diagnostic Accuracy, Laboratory Throughput, Distribution Network, and Regional Presence Supplier Qualification and Diagnostic Quality Compliance Capability Analysis Cholesterol Testing Kits and Testing Strips Positioning Automated Clinical Chemistry Platforms and Complete Lipid Profile Competitiveness Point-of-Care Testing, Portable Analyzers, and Home Healthcare Strategy Analysis Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Product Type, Test Type, Technology, Application, End User, Age Group, and Region (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Competitive Benchmarking of Leading Diagnostic Vendors Diagnostic Quality Compliance and Procurement Risk Analysis Technology Adoption Trends Across Enzymatic Assays, Colorimetric Testing, Electrochemical Biosensors, and Other Technologies List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Product Type, Test Type, Technology, Application, End User, and Age Group (2025 vs. 2032) Global Cholesterol Testing Ecosystem and Diagnostic Value Chain Analysis